Capital World Investors Takes Position in Arcellx, Inc. (NASDAQ:ACLX)

Capital World Investors bought a new stake in Arcellx, Inc. (NASDAQ:ACLX - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 252,878 shares of the company's stock, valued at approximately $19,393,000. Capital World Investors owned approximately 0.47% of Arcellx as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the business. Dimensional Fund Advisors LP grew its position in Arcellx by 156.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 305,088 shares of the company's stock valued at $23,400,000 after buying an additional 186,013 shares during the period. First Trust Advisors LP grew its position in shares of Arcellx by 274.3% during the 4th quarter. First Trust Advisors LP now owns 134,197 shares of the company's stock valued at $10,292,000 after acquiring an additional 98,340 shares during the period. Gilead Sciences Inc. purchased a new stake in shares of Arcellx during the 4th quarter worth approximately $515,418,000. EAM Investors LLC purchased a new position in Arcellx in the fourth quarter valued at approximately $3,298,000. Finally, Affinity Asset Advisors LLC lifted its stake in Arcellx by 6.3% in the fourth quarter. Affinity Asset Advisors LLC now owns 425,000 shares of the company's stock valued at $32,593,000 after purchasing an additional 25,000 shares during the last quarter. 96.03% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, insider Christopher Heery sold 10,155 shares of the stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $63.79, for a total value of $647,787.45. Following the sale, the insider now directly owns 37,486 shares of the company's stock, valued at approximately $2,391,231.94. This represents a 21.32 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Kavita Patel sold 1,500 shares of the firm's stock in a transaction that occurred on Tuesday, April 8th. The shares were sold at an average price of $57.50, for a total transaction of $86,250.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 54,455 shares of company stock valued at $3,408,458. Company insiders own 6.24% of the company's stock.

Arcellx Price Performance

Shares of ACLX traded up $0.34 during mid-day trading on Thursday, hitting $63.97. The stock had a trading volume of 441,870 shares, compared to its average volume of 556,682. Arcellx, Inc. has a 52 week low of $47.88 and a 52 week high of $107.37. The business has a fifty day moving average price of $64.80 and a 200-day moving average price of $74.96. The firm has a market cap of $3.51 billion, a P/E ratio of -90.10 and a beta of 0.33.

Arcellx (NASDAQ:ACLX - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.24). The firm had revenue of $15.27 million during the quarter, compared to the consensus estimate of $27.42 million. Arcellx had a negative net margin of 25.94% and a negative return on equity of 8.28%. As a group, research analysts expect that Arcellx, Inc. will post -1.58 earnings per share for the current fiscal year.

Arcellx Profile

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).